Clinical postdoctoral research fellowships are offered to support postdoctoral research training related to cystic fibrosis. These awards are intended to enable training in new research areas and methods to advance the scientific knowledge of the applicant and to collect data to enable their transition into an impactful research career.
Site Search
The Cystic Fibrosis Foundation is requesting applications with a letter of intent for innovative registry-based analyses that aim to test novel methods to advance the use of the Foundation’s Patient Registry.
I felt unrelenting hope watching the first plenary of this year’s North American Cystic Fibrosis Conference. As I learned about progress that has been made in sickle cell disease, and how those learnings may help us develop a genetic therapy for CF, it showed me that the CF community is supporting people like me who can’t take modulators.
The Research Additional Mentoring Program (RAMP) Award is designed to enable promising early-career physician scientists seeking additional research mentoring outside of their home academic institutions to enhance their clinical or translational research proficiency and support their development of the necessary clinical research capabilities to become independent investigators.
Foundation to fund up to $110 million for collaboration to accelerate the development of genetic therapies for CF
The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.
Nonprofit issues challenge to accelerate treatments for every person with CF
The Cystic Fibrosis Foundation is the world's leader in the fight against CF, and our scientific portfolio reflects our drive to provide effective treatments and — one day — a cure to every individual with this disease.
Today, the Cystic Fibrosis Foundation announced that it awarded funding to enGene Inc. to develop a customized vehicle to deliver genetic-based therapies, such as gene therapy and gene editing, into the lung cells of people with cystic fibrosis (CF). Delivering genetic-based therapies to the lungs is a key hurdle to developing effective treatments for all people with CF, including individuals with two nonsense and rare mutations.